Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2018-12-28 M&A Activity
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(특허권 양수 결정)
M&A Activity Classification · 95% confidence The document is a regulatory filing from Hyundai Bioscience regarding a 'Decision to Acquire Patent Rights' (특허권 양수 결정). It details the acquisition of patents from a major shareholder, including the contract amount, payment terms, and strategic purpose. This type of disclosure regarding significant asset acquisitions or major business decisions is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or capital change, as it pertains to a material corporate event reported to the exchange.
2018-12-28 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2018-12-14 Korean
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Hyundai Bioscience Co., Ltd. covering the period from January 1, 2018, to September 30, 2018. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.